StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Friday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright cut their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a […]